Oruka Therapeutics price target raised to $72 from $47 at Stifel

Stifel raised the firm’s price target on Oruka Therapeutics (ORKA) to $72 from $47 and keeps a Buy rating on the shares following the company’s Q4 release. ORKA now expects Phase 2 psoriasis data from ORKA-001 in Q2 and this update significantly moves up the timing of the company’s first clinical readout, says the analyst, who expects to see shares “react favorably towards increased proximity to the update.”